Cardio Diagnostics
Get Started
Hero Background

CardioInnovate360™

BioPharma Research Platform

Cardiovascular Disease

For the Discovery, Development, and Validation of Next Generation Cardiovascular Solutions

Epigenetics-based therapies are the next evolution in cardiovascular care and treatment, offering unprecedented opportunities to target the underlying mechanisms of cardiovascular disease.

CardioInnovate360 leverages AI and epigenetics to enable and accelerate the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Core Capabilities of the CardioInnovate360 Platform

1

1. Novel Biomarkers

Identify novel epigenetic and genetic biomarkers and pathways implicated in the pathogenesis of cardiovascular disease and associated co-morbidities.

2. Clinical Trials Optimization

Stratify patients more effectively for clinical trials by selecting those with a higher likelihood of responding to the investigational therapy or by providing more granular outcomes.

2

3

3. Custom Development

Develop custom post-market surveillance or companion diagnostic tests that are non-invasive and scalable.

Partner With Us to Improve Clinical Trial Design, Outcomes, and Advance Cardiovascular Innovation

Contact Us

Who We Serve

PatientsProvidersEmployers

Our Solutions

OverviewEpi+Gen CHD™PrecisionCHD™HeartRisk™CardioInnovate360™

Company

About UsAbout CVDCareersTechnologyResourcesContact Us

Investors

Stock InformationSEC FilingsPress ReleasesPresentationsEmail SubscriptionCorporate GovernanceContact Investor Relations
Contact Us

2026 Cardio Diagnostics, Inc.

Privacy PolicyTerms of UseHIPAA Notice

The Cardio Diagnostics clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical laboratory testing. The Epi+Gen CHD™ and PrecisionCHD™ tests were developed, and their performance characteristics were determined by Cardio Diagnostics. These tests should be ordered by a licensed healthcare provider, and test results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms, and other relevant clinical information. These tests are intended for clinical purposes and have not been cleared or approved by the U.S. Food and Drug Administration (FDA).

For the Epi+Gen CHD™ test, a lower risk result does not eliminate the possibility of a coronary heart disease event occurring or that coronary heart disease is present, and a higher risk result does not imply a diagnosis of coronary heart disease or that a coronary heart disease event will occur. For the PrecisionCHD™ test, a "Signal Detected" result is not a diagnosis of coronary heart disease, and a "Signal Not Detected" result does not eliminate the possibility that coronary heart disease is present or could occur in the future. False positive and false negative test results do occur. Rx only.

In addition to a federal CLIA license, the Cardio Diagnostics clinical laboratory holds active state clinical laboratory licenses in California, Maryland, Pennsylvania, and Rhode Island. The laboratory is not currently licensed to process patient samples originating from the state of New York.